Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
Stocks · News reference
Cingulate Announces Publication Of CTx-1301 Comparative Bioavailability Study In CNS Drugs, Says Trimodal ADHD Candidate Showed Higher Late-Day Plasma Levels And Fewer Adverse Events vs. Bimodal Comparator
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14) per share from the